The Centre is in consultations with the Russian authorities for exploring the potential of cooperation between the 2 nations for advancing the COVID-19 vaccine in India, Parliament was advised on Friday.
The Central Drugs Standard Control Organisation (CDSCO) has knowledgeable that it has acquired details about one COVID-19 vaccine developed and authorised in Russia, Minister of State for Health Ashwini Choubey knowledgeable the Lok Sabha.
Further, the Indian Council of Medical Research (ICMR), an autonomous organisation beneath the Department of Health Research, has knowledgeable that as per data out there from WHO draft panorama of COVID-19 vaccine (final replace on September 17), globally there are 36 candidate vaccines that are beneath numerous phases of scientific trials.
“Of this only 02 are Indian candidates (Bharat Biotech International Ltd. and Cadila Healthcare). All the 36 candidates are under various stages of clinical trials. None of the candidate vaccine so far has completed all stages of clinical trial,” he mentioned in a written reply.
In response to a query on whether or not the federal government is in talks with Russia and different nations to obtain COVID-19 vaccine doses within the upcoming months, Mr Choubey mentioned, “The Department of Biotechnology has informed that the Government of India is in consultations with the Russian Government for exploring the possibility of cooperation with Russia for advancing COVID-19 Vaccine in India.”
Further, Phase II and III bridging research of ChAdOx1-S, a vaccine developed by University of Oxford/AstraZeneca have been initiated in India.
“While the government and Industry are trying their best to make available a safe and effective vaccine for COVID-19 at the earliest, it is difficult to comment on the exact timelines in view of various complex pathways involved in vaccine development,” the minister underlined.
Elaborating on the steps taken by the federal government for well timed availability of COVID-19 medicine and vaccination, Mr Choubey knowledgeable that CDSCO has authorised the manufacturing and advertising and marketing of three medicine — Remdesivir Injectable formulations, Favipiravir tablets, Itolizumab injection — for restricted emergency use within the nation for therapy of coronavirus an infection.
Further, the CDSCO has granted permission for conduct of part I and II scientific trials of the 2 vaccine candidates indigenously developed by Bharat Biotech in collaboration with ICMR and Cadila Healthcare Ltd.
Besides, it has additionally given permission to the Serum Institute of India to conduct part II and III scientific trial of the Oxford COVID-19 vaccine, the minister mentioned.
(Except for the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)